Detalles de la búsqueda
1.
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.
J Pharmacol Exp Ther
; 363(2): 136-147, 2017 11.
Artículo
Inglés
| MEDLINE | ID: mdl-28847917
2.
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Sci Transl Med
; 16(734): eadj5962, 2024 Feb 14.
Artículo
Inglés
| MEDLINE | ID: mdl-38354228
3.
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts.
Mol Cancer Ther
; 23(5): 662-671, 2024 May 02.
Artículo
Inglés
| MEDLINE | ID: mdl-38224566
4.
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
Neurooncol Adv
; 5(1): vdad066, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37324218
5.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Neuro Oncol
; 24(3): 384-395, 2022 03 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34232318
6.
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Neurooncol Adv
; 4(1): vdac130, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-36071925
7.
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks.
Cancer Res
; 81(14): 3930-3941, 2021 07 15.
Artículo
Inglés
| MEDLINE | ID: mdl-34016623
8.
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
Mol Cancer Ther
; 20(6): 1009-1018, 2021 06.
Artículo
Inglés
| MEDLINE | ID: mdl-33785646
9.
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Mol Cancer Ther
; 16(12): 2735-2746, 2017 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-28947502
10.
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Mol Cancer Ther
; 15(6): 1332-43, 2016 06.
Artículo
Inglés
| MEDLINE | ID: mdl-27196784
11.
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
J Natl Cancer Inst
; 108(5)2016 May.
Artículo
Inglés
| MEDLINE | ID: mdl-26615020
12.
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Clin Cancer Res
; 21(8): 1916-24, 2015 Apr 15.
Artículo
Inglés
| MEDLINE | ID: mdl-25609063
13.
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Clin Cancer Res
; 20(14): 3730-41, 2014 Jul 15.
Artículo
Inglés
| MEDLINE | ID: mdl-24838527
Resultados
1 -
13
de 13
1
Próxima >
>>